Cargando…

Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status

SIMPLE SUMMARY: Preclinical studies have shown an anti-neoplastic effect of progestins against adrenal cortical carcinoma. Progestins have a positive effect on patient cenesthesia and may make standard chemotherapy more tolerable. In this study, the addition of megestrol acetate to the etoposide, do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turla, Antonella, Laganà, Marta, Abate, Andrea, Cremaschi, Valentina, Zamparini, Manuel, Chittò, Matteo, Consoli, Francesca, Alberti, Andrea, Ambrosini, Roberta, Tamburello, Mariangela, Grisanti, Salvatore, Tiberio, Guido Alberto Massimo, Sigala, Sandra, Cosentini, Deborah, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527072/ https://www.ncbi.nlm.nih.gov/pubmed/37760461 http://dx.doi.org/10.3390/cancers15184491

Ejemplares similares

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
por: Rossini, Elisa, et al.
Publicado: (2021)

Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
por: Laganà, M., et al.
Publicado: (2022)

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
por: Delbarba, Andrea, et al.
Publicado: (2023)

Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
por: Tamburello, Mariangela, et al.
Publicado: (2023)

Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
por: Fiorentini, Chiara, et al.
Publicado: (2019)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
por: Rossini, Elisa, et al.
Publicado: (2021)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
por: Abate, Andrea, et al.
Publicado: (2020)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
por: Ambrosini, Roberta, et al.
Publicado: (2020)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
por: Cosentini, Deborah, et al.
Publicado: (2021)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
por: Sigala, Sandra, et al.
Publicado: (2022)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

An update on adrenocortical cell lines of human origin
por: Sigala, Sandra, et al.
Publicado: (2022)

Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
por: Sigala, Sandra, et al.
Publicado: (2023)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study
por: Tiberio, Guido Alberto Massimo, et al.
Publicado: (2020)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Treatment and outcome of metastatic parathyroid carcinoma: A systematic review and pooled analysis of published cases
por: Alberti, Andrea, et al.
Publicado: (2022)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma
por: Weng, Yan, et al.
Publicado: (2023)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ag0pvlqb5nsjcartkq2ei1vrui